RU2013133874A - Ингенол-3-ацилаты iii и ингенол-3-карбаматы - Google Patents

Ингенол-3-ацилаты iii и ингенол-3-карбаматы Download PDF

Info

Publication number
RU2013133874A
RU2013133874A RU2013133874/04A RU2013133874A RU2013133874A RU 2013133874 A RU2013133874 A RU 2013133874A RU 2013133874/04 A RU2013133874/04 A RU 2013133874/04A RU 2013133874 A RU2013133874 A RU 2013133874A RU 2013133874 A RU2013133874 A RU 2013133874A
Authority
RU
Russia
Prior art keywords
ingenol
carboxylate
alkyl
methyl
compound according
Prior art date
Application number
RU2013133874/04A
Other languages
English (en)
Other versions
RU2572549C2 (ru
Inventor
Гуннар ГРУЭ-СЕРЕНСЕН
Сифу Лян
Томас ХЕГБЕРТ
Кристоффер МОНССОН
Пер ВЕДСЕ
Томас ВИФИАН
Original Assignee
Лео Лэборетериз Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лео Лэборетериз Лимитед filed Critical Лео Лэборетериз Лимитед
Publication of RU2013133874A publication Critical patent/RU2013133874A/ru
Application granted granted Critical
Publication of RU2572549C2 publication Critical patent/RU2572549C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/06—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by nitrosation of hydrocarbons or substituted hydrocarbons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/36—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/38—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/21—Radicals derived from sulfur analogues of carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D333/40—Thiophene-2-carboxylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/86—Ring systems containing bridged rings containing four rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Cosmetics (AREA)

Abstract

1. Соединение общей формулы Iгде R обозначает гетероарил, который может быть необязательно замещен одним или более заместителями, независимо выбранными из R7;или R обозначает гетероциклоалкил или гетероциклоалкенил, где указанный гетероциклоалкил или гетероциклоалкенил необязательно замещены одним или более заместителями, независимо выбранными из R8;или R обозначает X;R7 представляет галоген, циано или гидроксил;или R7 представляет (C-C)алкил, (C-C)алкенил, (C-C)циклоалкил, гетероциклоалкил, арил, гетероарил, арилалкил, гетероциклоалкилалкил или (C-C)циклоалкилалкил, где указанные (C-C)алкил, (C-C)алкенил, (C-C)циклоалкил, гетероциклоалкил, арил, гетероарил, арилалкил, гетероциклоалкилалкил или (C-C)циклоалкилалкил необязательно замещены одним или более заместителями, независимо выбранными из R9;или R7 представляет -NRaCORb, -CONRaRb, -COORc, -OCORa, -ORa, -OCONRaRb, -NRaCOORb, -NRaCONRaRb, -NRaSO2NRaRb, -NRaSO2Rb, -SO2NRaRb, -SO2Ra, -S(O)Ra, -SRa или -NRaRb;R9 представляет галоген, циано, гидрокси, (C-C)алкил, галоген(C-C)алкил, -NRaCORb, -COORc, -OCORa, -CONRaRb, -OCONRaRb, -NRaCOORb, -NRaCONRaRb, -NRaSO2NRaRb, -NRaSO2Rb, -SO2NRaRb, -SO2Ra, -S(O)Ra, -ORa, -SRa или =O;R8 представляет галоген, циано или гидроксил;или R8 представляет (C-C)алкил, (C-C)алкенил, арил, гетероарил, (C-C)циклоалкил или гетероциклоалкил, где указанные (C-C)алкил, (C-C)алкенил, арил, гетероарил, (C-C)циклоалкил или гетероциклоалкил необязательно замещены одним или более заместителями, независимо выбранными из R10,или R8 представляет -NRaCORb, -COORc, -OCORa, -CONRaRb, -OCONRaRb, -NRaCOORb, -NRaCONRaRb, -NRaSO2NRaRb, -NRaSO2Rb, -SO2NRaRb, -SO2Ra, -S(O)Ra, -ORa, -SRa, =O, =N-ORa, -O-N=CRaRb, NRaRb или -C(O)N(Ra)O-Rb;R10 представляет галоген, циано, гидрокси, (C-C)алкил, (C-C)алкокси, галоген(C-C)алкил, галоген(C-C)алкокси, гидрокси(C-C)алкил, циано(C-C)алкил, арил, гетероарил, циклоалкил, гетероци�

Claims (46)

1. Соединение общей формулы I
Figure 00000001
где R обозначает гетероарил, который может быть необязательно замещен одним или более заместителями, независимо выбранными из R7;
или R обозначает гетероциклоалкил или гетероциклоалкенил, где указанный гетероциклоалкил или гетероциклоалкенил необязательно замещены одним или более заместителями, независимо выбранными из R8;
или R обозначает X;
R7 представляет галоген, циано или гидроксил;
или R7 представляет (C1-C4)алкил, (C2-C4)алкенил, (C3-C7)циклоалкил, гетероциклоалкил, арил, гетероарил, арилалкил, гетероциклоалкилалкил или (C3-C7)циклоалкилалкил, где указанные (C1-C4)алкил, (C2-C4)алкенил, (C3-C7)циклоалкил, гетероциклоалкил, арил, гетероарил, арилалкил, гетероциклоалкилалкил или (C3-C7)циклоалкилалкил необязательно замещены одним или более заместителями, независимо выбранными из R9;
или R7 представляет -NRaCORb, -CONRaRb, -COORc, -OCORa, -ORa, -OCONRaRb, -NRaCOORb, -NRaCONRaRb, -NRaSO2NRaRb, -NRaSO2Rb, -SO2NRaRb, -SO2Ra, -S(O)Ra, -SRa или -NRaRb;
R9 представляет галоген, циано, гидрокси, (C1-C4)алкил, галоген(C1-C4)алкил, -NRaCORb, -COORc, -OCORa, -CONRaRb, -OCONRaRb, -NRaCOORb, -NRaCONRaRb, -NRaSO2NRaRb, -NRaSO2Rb, -SO2NRaRb, -SO2Ra, -S(O)Ra, -ORa, -SRa или =O;
R8 представляет галоген, циано или гидроксил;
или R8 представляет (C1-C4)алкил, (C1-C4)алкенил, арил, гетероарил, (C3-C7)циклоалкил или гетероциклоалкил, где указанные (C1-C4)алкил, (C2-C4)алкенил, арил, гетероарил, (C3-C7)циклоалкил или гетероциклоалкил необязательно замещены одним или более заместителями, независимо выбранными из R10,
или R8 представляет -NRaCORb, -COORc, -OCORa, -CONRaRb, -OCONRaRb, -NRaCOORb, -NRaCONRaRb, -NRaSO2NRaRb, -NRaSO2Rb, -SO2NRaRb, -SO2Ra, -S(O)Ra, -ORa, -SRa, =O, =N-ORa, -O-N=CRaRb, NRaRb или -C(O)N(Ra)O-Rb;
R10 представляет галоген, циано, гидрокси, (C1-C4)алкил, (C1-C4)алкокси, галоген(C1-C4)алкил, галоген(C1-C4)алкокси, гидрокси(C1-C4)алкил, циано(C1-C4)алкил, арил, гетероарил, циклоалкил, гетероциклоалкил, -NRaCORb, -COORc, -OCORa, -CONRaRb, -OCONRaRb, -NRaCOORb, -NRaCONRaRb, -NRaSO2NRaRb, -NRaSO2Rb, -SO2NRaRb, -SO2Ra, -S(O)Ra, -ORa, -SRa или =O;
Ra и Rb представляют водород, (C1-C4)алкил, галоген(C1-C4)алкил, (C1-C4)алкокси(C1-C4)алкил, гидрокси(C1-C4)алкил, циано(C1-C4)алкил, арил, гетероарил, циклоалкил или гетероциклоалкил;
Rc представляет водород, (C1-C4)алкил, галоген(C1-C4)алкил, (C1-C4)алкокси(C1-C4)алкил, гидрокси(C1-Cx)алкил, циано(C1-Cx)алкил, арил, гетероарил, циклоалкил или гетероциклоалкил;
X представляет -NR11R12
где R11 и R12 независимо представляют водород,
или где R11 и R12 независимо представляют (C1-C6)алкил, (C2-C6)алкенил или (C2-C6)алкинил, циклоалкил, циклоалкенил, арил, гетероарил, гетероциклоалкил, гетероциклоалкенил, циклоалкилалкил, циклоалкенилалкил, арилалкил, гетероарилалкил, гетероциклоалкилалкил, гетероциклоалкенилалкил, алкилциклоалкил, алкилциклоалкенил, алкиларил, алкилгетероарил или алкилгетероциклоалкил, где указанные (C1-C6)алкил, (C2-C6)алкенил или (C2-C6)алкинил, циклоалкил, циклоалкенил, арил, гетероарил, гетероциклоалкил, гетероциклоалкенил, циклоалкилалкил, циклоалкенилалкил, арилалкил, гетероарилалкил, гетероциклоалкилалкил, гетероциклоалкенилалкил, алкилциклоалкил, алкилциклоалкенил, алкиларил, алкилгетероарил или алкилгетероциклоалкил необязательно замещены одним или более заместителями, независимо выбранными из R13;
R13 представляет галоген, циано или гидроксил,
или R13 представляет (C1-C4)алкил, (C2-C4)алкенил, арил, (C3-C7)циклоалкил, гетероарил или гетероциклоалкил, где указанные (C1-C4)алкил, (C2-C4)алкенил, арил, (C3-C7)циклоалкил, гетероарил или гетероциклоалкил необязательно замещены одним или более заместителями, независимо выбранными из R14
или R13 представляет -NRdCORe, -COORf, -OCORd, -CONRdRe, -OCONRdRe, -NRdCOORe, -NRdCONRdRe, -NRdSO2Re, -NRdSO2NRdRe, -SO2NRdRe, -SO2Rd, -S(O)Rd, -ORd, -SRd, =O, =N-ORd, -O-N=CRdRe, -NRdRe или -C(O)N(Rd)-Ore,
где Rd и Re независимо представляют водород, (C1-C4)алкил, галоген(C1-C4)алкил, (C1-C4)алкокси(C1-C4)алкил, гидрокси(C1-C4)алкил, циано(C1-C4)алкил, арил, гетероарил, циклоалкил или гетероциклоалкил;
Rf представляет водород, (C1-C4)алкил, галоген(C1-C4)алкил, (C1-C4)алкокси(C1-C4)алкил, гидрокси(C1-C4)алкил, циано(C1-C4)алкил, арил, гетероарил, циклоалкил или гетероциклоалкил;
R14 представляет водород, гидроксил, циано, (C1-C4)алкил, (C1-C4)алкокси, галоген(C1-C4)алкил, галоген(C1-C4)алкокси, гидрокси(C1-C4)алкил, циано(C1-C4)алкил, арил, гетероарил, циклоалкил, гетероциклоалкил, -NRdCORe, -COORf, -OCORd, -CONRdRe, -OCONRdRe, -NRdCOORe, -NRdCONRdRe, -NRdSO2Re, -NRdSO2NRdRe, -SO2NRdRe, -SO2Rd, -S(O)Rd, -ORd, -SRd или =O;
и его фармацевтически приемлемые соли, пролекарства, гидраты и сольваты.
2. Соединение по п.1, где R обозначает гетероарил, который может необязательно быть замещен одним или более заместителями, независимо выбранными из R7,
или R обозначает гетероциклоалкил или гетероциклоалкенил, каждый из которых может необязательно быть замещен одним или более заместителями, независимо выбранными из R8,
R7 представляет галоген, циано, гидрсил;
или R7 представляет (C1-C4)алкил, (C2-C4)алкенил, (C3-C7)циклоалкил, гетероциклоалкил, арил, гетероарил, каждый из которых необязательно замещен одним или более заместителями, независимо выбранными из R9;
или R7 представляет -NRaCORb, -CONRaRb, -COORc, -OCORa, -ORa, -OCONRaRb, -NRaCOORb, -NRaCONRaRb, -NRaSO2NRaRb, -NRaSO2Rb, -SO2NRaRb, -SO2Ra, -S(O)Ra, -SRa;
R9 представляет галоген, циано, гидрокси (C1-C4)алкил, галоген(C1-C4)алкил, -NRaCORb, -COORc, -OCORa, -CONRaRb, -OCONRaRb, -NRaCOORb, -NRaCONRaRb, -NRaSO2NRaRb, -NRaSO2Rb, -SO2NRaRb, -SO2Ra, -S(O)Ra, -ORa, -SRa, =O;
R8 представляет галоген, циано, гидроксил;
или R8 представляет (C1-C4)алкил, (C1-C4)алкенил, арил, гетероарил, (C3-C7)циклоалкил, гетероциклоалкил, каждый из которых необязательно замещен одним или более заместителями, независимо выбранными из R10,
или R8 представляет -NRaCORb, -COORc, -OCORa, -CONRaRb, -OCONRaRb, -NRaCOORb, -NRaCONRaRb, -NRaSO2NRaRb, -NRaSO2Rb, -SO2NRaRb, -SO2Ra, -S(O)Ra, -ORa, -SRa, =O;
R10 представляет галоген, циано, гидрокси, (C1-C4)алкил, галоген(C1-C4)алкил, -NRaCORb, -COORc, -OCORa, -CONRaRb, -OCONRaRb, -NRaCOORb, -NRaCONRaRb, -NRaSO2NRaRb, -NRaSO2Rb, -SO2NRaRb, -SO2Ra, -S(O)Ra, -ORa, -SRa, =O;
Ra и Rb представляют водород, (C1-C4)алкил, галоген(C1-C4)алкил, (C1-C4)алкокси(C1-C4)алкил, гидрокси(C1-C4)алкил, циано(C1-C4)алкил;
Rc представляет (C1-C4)алкил, галоген(C1-C4)алкил, (C1-C4)алкокси(C1-C4)алкил, гидрокси(C1-C4)алкил, циано(C1-C4)алкил.
3. Соединение по п.1, где R обозначает гетероарил.
4. Соединение по п.3, где гетероарил представляет изоксазолил, пиридил, хинолил, изохинолил, индолил, фурил, тиазолил, имидазолил, пиразолил, оксазолил, тиенил, пиримидинил, 1,2,3-триазолил, индазолил, циннолил, 1,2-бензоксазолил, имидазотиазолил, имидазопиридинил, пирролил, изотиазолил, тетрагидроиндазолил или оксадиазолил.
5. Соединение по любому из пп.1-4, где R7 независимо выбран один или более раз из группы (C1-C4)алкила, (C2-C4)алкенила, арила, арилалкила, гетероциклоалкилалкила, (C3-C7)-циклоалкилалкила, (C3-C7)-циклоалкила, -COORc, -ORa или галогена.
6. Соединение по п.5, где R7 выбран из фенила, метила, этила, изопропила, т-бутила, пиперидила, трет-бутилоксикарбонила, бензила, тетрагидропиранилметила, -OCH3, циклопропила, аллила, циклопропилметила, Cl, Br или I.
7. Соединение по любому из пп.1-4, где R9 обозначает галоген, -ORa, (C1-C4)алкил или -SO2Ra.
8. Соединение по п.7, где R9 обозначает Cl, F, -OCH3, метил или метилсульфонил.
9. Соединение по п.1, где R обозначает гетероциклоалкил или гетероциклоалкенил.
10. Соединение по п.9, где гетероциклоалкил или гетероциклоалкенил представляет пирролидинил, пиперидинил, морфолинил, 5-оксабицикло[2.2.2]октанил, оксаспиро[4.5]дец-1-енил, оксотиазолил, дигидротиазолил, оксопиранил, азепанил, азабицикло[3.2.2]нонанил, бензоксазинил, хиноксалинил, изоиндолинил, дигидрохинолинил, индолинил или дигидрохиноксалинил.
11. Соединение по любому из пп.1, 2 или 9, где R8 обозначает (C1-C4)алкил, арил или =O.
12. Соединение по п.11, где R8 обозначает метил, фенил или =O.
13. Соединение по любому из пп.1, 2 или 9 где R10 представляет галоген.
14. Соединение по п.1, где R представляет -NR11R12.
15. Соединение по любому из пп.1 или 14, где R11 и R12 независимо представляют водород, (C1-C6)алкил, арил, циклоалкил, арилалкил, гетероарил, циклоалкилалкил, гетероарилалкил, гетероциклоалкил, гетероциклоалкилалкил, (C2-C6)алкенил или (C2-C6)алкинил.
16. Соединение по п.15, где R11 и R12 независимо представляют водород, метил, этил, изопропил, фенил, бензил, циклогексил, инданил, тетралинил, фенилэтил, циклопропилметил, пиразолил, изоксазолилметил, циклопентил, циклопропил, пиридил, пиперидил, тетрагидропиранилметил, тетрагидропиранил, циклобутил, аллил, пропинил или тиазолил.
17. Соединение по любому из пп.1 или 14, где R13 представляет (C1-C4)алкил, циано, галоген, =O, -ORa или -COORf.
18. Соединение по п.17, где R13 представляет метил, циано, F, =O, -OCH3 или -COOC(CH3)3.
19. Соединение по любому из пп.1 или 14, где R11 или R12 независимо представляет водород.
20. Соединение по любому из пп.1-4, 9 или 14, причем указанное соединение выбрано из группы, состоящей из:
Ингенол 3-(5-метил-3-фенилизоксазол-4-карбоксилат) или
Ингенол 3-(5-метил-3-(2-хлор-6-фторфенил)-изоксазол-4-карбоксилат),
Ингенол 3-(1S-камфанат),
Ингенол 3-(3-фенилтриазол-4-карбоксилат),
Ингенол 3-(2-фенилпиразол-3-карбоксилат),
Ингенол 3-(1-метилиндазол-3-карбоксилат),
Ингенол 3-(3-этил-5-метилизоксазол-4-карбоксилат),
Ингенол 3-(3-метил-5-метилизоксазол-4-карбоксилат),
Ингенол 3-(1-метилиндол-3-карбоксилат),
Ингенол 3-(3-фенилтиофен-2-карбоксилат),
Ингенол 3-(5-фенилизоксазол-3-карбоксилат),
Ингенол 3-(N-этил-карбамат),
Ингенол 3-(Н,Н-диметилкарбамат),
Ингенол 3-(морфолин-4-карбоксилат),
Ингенол 3-(пирролидин-1-карбоксилат),
Ингенол 3-(N-метил-N-фенилкарбамат),
Ингенол 3-(Н,Н-диэтилкарбамат),
Ингенол 3-(пиперидин-1-карбоксилат),
Ингенол 3-(N-бензил-N-метилкарбамат),
Ингенол 3-(N-циклогексил-N-метилкарбамат),
Ингенол 3-(N-циклогексилкарбамат),
Ингенол 3-(N-фенилкарбамат),
Ингенол 3-(N-(индан-1-ил)карбамат),
Ингенол 3-(3,3-диметилпиперидин-1-карбоксилат),
Ингенол 3-(N-метил-N-тетралин-1-ил-карбамат),
Ингенол 3-(N-(2-циано-1-метил-этил)-N-метилкарбамат),
Ингенол 3-(N-метил-N-((S)-1-фенэтил)карбамат),
Ингенол 3-(N-метил-N-(циклопропилметил)карбамат),
Ингенол 3-(изохинолин-1-карбоксилат),
Ингенол 3-(хинолин-4-карбоксилат),
Ингенол 3-(циннолин-4-карбоксилат),
Ингенол 3-(3-фенилимидазол-4-карбоксилат),
Ингенол 3-(5-фенилоксазол-4-карбоксилат),
Ингенол 3-(1,2-бензоксазол-3-карбоксилат),
Ингенол 3-(3-изопропил-5-метилизоксазол-4-карбоксилат),
Ингенол 3-(3-(2-метоксифенил)-5-метилизоксазол-4-карбоксилат),
Ингенол 3-(4-бром-2-метилпиразол-3-карбоксилат),
Ингенол 3-(4-бром-2-этилпиразол-3-карбоксилат),
Ингенол 3-(4-хлор-2-метилпиразол-3-карбоксилат),
Ингенол 3-(5-бромпиримидин-4-карбоксилат),
Ингенол 3-(3-бромпиридин-2-карбоксилат),
Ингенол 3-(5-метилтиазол-4-карбоксилат),
Ингенол 3-(4-хлор-1-метилпиразол-3-карбоксилат),
Ингенол 3-(2,4-диметилтиазол-5-карбоксилат),
Ингенол 3-(2,5-диметилоксазол-4-карбоксилат),
Ингенол 3-(2,4-диметилфуран-3-карбоксилат),
Ингенол 3-(3,5-диэтилизоксазол-4-карбоксилат),
Ингенол 3-(N-(3-фторфенил)-N-метилкарбамат),
Ингенол 3-(N-(2,5-диметилпиразол-3-ил)-N-метилкарбамат),
Ингенол 3-(1H-индол-7-карбоксилат),
Ингенол 3-(2-трет-бутил-5-метилпиразол-3-карбоксилат),
Ингенол 3-(5-трет-бутил-2-метилпиразол-3-карбоксилат),
Ингенол 3-(6-метилимидазо[2,1-b]тиазол-5-карбоксилат),
Ингенол 3-(2-метилимидазо[1,2-a]пиридин-3-карбоксилат),
Ингенол 3-(2,4,5-триметилфуран-3-карбоксилат),
Ингенол 3-(3-метилтиофен-2-карбоксилат),
Ингенол 3-(2-метил-4-(1-пиперидил)пиразол-3-карбоксилат),
Ингенол 3-(2-хлор-5-изопропил-тиазол-4-карбоксилат),
Ингенол 3-(4-хлор-2,5-диметилпиразол-3-карбоксилат),
Ингенол 3-(1,2,4-триметилпиррол-3-карбоксилат),
Ингенол 3-(1,3,5-триметилпиррол-2-карбоксилат),
Ингенол 3-(1-этил-3,5-диметилпиррол-2-карбоксилат),
Ингенол 3-(1-трет-бутилоксикарбонил-3,3-диметилпирролидин-2-карбоксилат),
Ингенол 3-((2S)-1-фенилпирролидин-2-карбоксилат),
Ингенол 3-(1-изопропил-3,5-диметилпиразол-4-карбоксилат),
Ингенол 3-(5-этил-3-изопропил-изоксазол-4-карбоксилат),
Ингенол 3-(2-метилиндазол-3-карбоксилат),
Ингенол 3-(5-метил-3-трет-бутилизоксазол-4-карбоксилат),
Ингенол 3-(2-метил-3-оксо-4-оксаспиро[4.5]дец-1-ен-1-карбоксилат),
Ингенол 3-(1-трет-бутил-3,5-диметилпиразол-4-карбоксилат),
Ингенол 3-(3,5-диметилизотиазол-4-карбоксилат),
Ингенол 3-(5-йод-3-метил-изотиазол-4-карбоксилат),
Ингенол 3-(4-(4-метоксифенил)-2-метилпиразол-3-карбоксилат),
Ингенол 3-(4-(2-метилфенил)-2-метилпиразол-3-карбоксилат),
Ингенол 3-(2-метил-4-(4-метилсульфонилфенил)пиразол-3-карбоксилат),
Ингенол 3-(2-метил-4-фенилпиразол-3-карбоксилат),
Ингенол 3-(3,5-диметил-1-фенилпиразол-4-карбоксилат),
Ингенол 3-(1,5-диметил-3-фенилпиразол-4-карбоксилат),
Ингенол 3-(1-бензил-3,5-диметилпиразол-4-карбоксилат),
Ингенол 3-(3,5-диметил-1-(тетрагидропиран-4-илметил)пиразол-4-карбоксилат),
Ингенол 3-(4-метил-2-оксо-3H-тиазол-5-карбоксилат),
Ингенол 3-(2-метил-4,5,6,7-тетрагидроиндазол-3-карбоксилат),
Ингенол 3-(1,2-диметилиндол-3-карбоксилат),
Ингенол 3-(5-метокси-1,2-диметилиндол-3-карбоксилат),
Ингенол 3-(1,3,5-триметилпиразол-4-карбоксилат),
Ингенол 3-(4-метил-1,2,5-оксадиазол-3-карбоксилат),
Ингенол 3-(2-метокси-4-метилтиазол-5-карбоксилат),
Ингенол 3-(4,5-диметилизоксазол-3-карбоксилат),
Ингенол 3-(4-бром-1-метилпиразол-3-карбоксилат),
Ингенол 3-(1,3-диметилиндол-2-карбоксилат),
Ингенол 3-(5-метокси-1,3-диметилиндол-2-карбоксилат),
Ингенол 3-(2,4-диметил-6-оксопиран-3-карбоксилат),
Ингенол 3-(1-метил-3-фенилиндол-2-карбоксилат),
Ингенол 3-(3-метил-5-(трифторметил)изоксазол-4-карбоксилат),
Ингенол 3-(1,3-диметилпиррол-2-карбоксилат),
Ингенол 3-(3,5-диметил-1-(2,2,2-трифторэтил)пиразол-4-карбоксилат),
Ингенол 3-(1-циклопропил-2,5-диметилпиррол-3-карбоксилат),
Ингенол 3-(1,2,5-триметилпиррол-3-карбоксилат),
Ингенол 3-(2,4-диметил-1H-пиррол-3-карбоксилат),
Ингенол 3-(1-метилпиррол-2-карбоксилат),
Ингенол 3-(4-метил-1H-пиррол-2-карбоксилат),
Ингенол 3-(1,5-диметилпиррол-2-карбоксилат),
Ингенол 3-(3-метил-1H-пиррол-2-карбоксилат),
Ингенол 3-(1-циклопропилпиррол-2-карбоксилат),
Ингенол 3-(1-этил-2,4-диметилпиррол-3-карбоксилат),
Ингенол 3-(1-аллил-2,4-диметилпиррол-3-карбоксилат),
Ингенол 3-(1-(циклопропилметил)-2,4-диметилпиррол-3-карбоксилат),
Ингенол 3-(1-(2-метоксиэтил)-2,4-диметилпиррол-3-карбоксилат),
Ингенол 3-(N-(3,5-диметилизоксазол-4-ил)-N-метилкарбамат),
Ингенол 3-(N-(1,5-диметилпиразол-3-ил)-N-метилкарбамат),
Ингенол 3-(N-циклопентил-N-метилкарбамат),
Ингенол 3-(N-циклопропил-N-метилкарбамат),
Ингенол 3-(N-метил-N-(2-пиридил)карбамат),
Ингенол 3-(4-оксо-2,3-дигидрохинолин-1-карбоксилат),
Ингенол 3-(3,4-дигидро-2H-хинолин-1-карбоксилат),
Ингенол 3-(индолин-1-карбоксилат),
Ингенол 3-(азепан-1-карбоксилат),
Ингенол 3-(N-(4-хлорфенил)-N-метилкарбамат),
Ингенол 3-(N-(4-фторфенил)-N-метилкарбамат),
Ингенол 3-(N-метил-N-(2-метоксифенил)карбамат),
Ингенол 3-(N-метил-N-(2-метилфенил)карбамат),
Ингенол 3-(3-оксо-2,4-дигидрохиноксалин-1-карбоксилат),
Ингенол 3-(N-этил-N-фенилкарбамат),
Ингенол 3-(2-трифторметилпирролидин-1-карбоксилат),
Ингенол 3-(3-азабицикло[3.2.2]нонан-3-карбоксилат),
Ингенол 3-(2,3-дигидро-1,4-бензоксазин-4-карбоксилат),
Ингенол 3-(N-(2-фторфенил)-N-метилкарбамат),
Ингенол 3-(3-метил-2,3-дигидро-1,4-бензоксазин-4-карбоксилат),
Ингенол 3-(2-трифторметилпирролидин-1-карбоксилат) (изомер A),
Ингенол 3-(2-трифторметилпирролидин-1-карбоксилат) (изомер B),
Ингенол 3-(N-метил-N-(N-(трет-бутилоксикарбонил)-4-пиперидил)карбамат),
Ингенол 3-(N-метил-N-(3-метилфенил)карбамат),
Ингенол 3-(3,4-дигидро-2H-хиноксалин-1-карбоксилат),
Ингенол 3-(изоиндолин-2-карбоксилат),
Ингенол 3-(N-метил-N-(тетрагидропиран-4-илметил)карбамат),
Ингенол 3-(N-метил-N-(тетрагидропиран-4-ил)карбамат),
Ингенол 3-(N-метил-N-(3-метоксифенил)карбамат),
Ингенол 3-(N-циклобутил-N-метилкарбамат),
Ингенол 3-(N-аллил-N-метилкарбамат),
Ингенол 3-(N-метил-N-проп-2-инилкарбамат),
Ингенол 3-(N-метил-N-(4-метилтиазол-2-ил)карбамат) или
Ингенол 3-(N-(4-цианофенил)-N-метилкарбамат).
21. Соединение по любому из пп.1-4, 9 или 14 для применения в качестве лекарственного препарата при лечении.
22. Соединение по любому из пп.1-4, 9 или 14 для применения при лечении, предотвращении, облегчении течения или профилактике физиологических расстройств или заболеваний, связанных с гиперплазией или неоплазией.
23. Соединение по п.22, где расстройство или заболевание выбрано из кожных бородавок, генитальных бородавок, актинового кератоза, плоскоклеточной карциномы (SCC), базальноклеточной карциномы (BCC), злокачественного лентиго, внутриэпителиальной неоплазии шейки матки, анальной внутриэпителиальной неоплазии или внутриэпителиальной неоплазии вульвы.
24. Применение соединения по любому из пп.1-4, 9 или 14 для получения фармацевтического лекарственного препарата.
25. Применение соединения по п.24 для получения лекарственного препарата для лечения, облегчения течения или профилактики физиологических расстройств или заболеваний, связанных с гиперплазией или неоплазией.
26. Применение по п.25, где расстройство или заболевание выбрано из кожных бородавок, генитальных бородавок, плоскоклеточной карциномы (SCC), базальноклеточной карциномы (BCC), злокачественного лентиго, внутриэпителиальной неоплазии шейки матки, анальной внутриэпителиальной неоплазии или внутриэпителиальной неоплазии вульвы.
27. Способ предотвращения, лечения, облегчения течения или профилактики физиологических расстройств или заболеваний, связанных с гиперплазией или неоплазией, введением нуждающемуся в нем индивиду соединения по любому из пп.1-4, 9 или 14.
28. Способ по п.27, где расстройство или заболевание выбрано из кожных бородавок, генитальных бородавок, плоскоклеточной карциномы (SCC), базальноклеточной карциномы (BCC), злокачественного лентиго, внутриэпителиальной неоплазии шейки матки, анальной внутриэпителиальной неоплазии или внутриэпителиальной неоплазии вульвы.
29. Соединение по любому из пп.1-4, 9 или 14 для применения при лечении или облегчении течения заболеваний или расстройств по косметическим показаниям.
30. Соединение по п.29, где косметическое показание выбрано из фотоповреждения кожи или себоррейного кератоза.
31. Применение соединения по п.24 для получения лекарственного препарата для лечения или облегчения течения заболеваний или расстройств по косметическим показаниям.
32. Применение по п.31, где косметическое показание выбрано из фотоповреждения кожи или себоррейного кератоза.
33. Способ лечения или облегчения течения заболеваний или расстройств по косметическим показаниям введением нуждающемуся в нем индивиду соединения по любому из пп.1-4, 9 или 14.
34. Способ по п.33, где косметическое показание выбрано из фотоповреждения кожи или себоррейного кератоза.
35. Применение соединения по п.24 при получении фармацевтической композиции для лечения или облегчения течения заболевания, расстройства или состояния, реагирующего на стимуляцию окислительного выброса нейтрофилов.
36. Применение соединения по п.24 при получении фармацевтической композиции для лечения или облегчения течения заболевания, расстройства или состояния, реагирующего на стимуляцию высвобождения IL-8 из кератиноцитов.
37. Применение соединения по п.24 при получении фармацевтической композиции для лечения или облегчения течения заболевания, расстройства или состояния, реагирующего на индукцию некроза.
38. Способ предотвращения, лечения, облегчения течения или профилактики физиологического заболевания или расстройства, реагирующего на стимуляцию окислительного выброса нейтрофилов, введением нуждающемуся в нем индивиду соединения по любому из пп.1-4, 9 или 14.
39. Способ предотвращения, лечения, облегчения течения или профилактики физиологического заболевания или расстройства, реагирующего на стимуляцию высвобождения IL-8 из кератиноцитов, введением нуждающемуся в нем индивиду соединения по любому из пп.1-4, 9 или 14.
40. Способ предотвращения, лечения, облегчения течения или профилактики физиологического заболевания или расстройства, реагирующего на индукцию некроза, введением нуждающемуся в нем индивиду соединения по любому из пп.1-4, 9 или 14.
41. Соединение по любому из пп.1-4, 9 или 14 для применения при лечении или облегчении течения заболевания, расстройства или состояния, реагирующего на стимуляцию окислительного выброса нейтрофилов.
42. Соединение по любому из пп.1-4, 9 или 14 для применения при лечении или облегчении течения заболевания, расстройства или состояния, реагирующего на стимуляцию высвобождения IL-8 из кератиноцитов.
43. Соединение по любому из пп.1-4, 9 или 14 для применения при лечении или облегчении течения заболевания, расстройства или состояния, реагирующего на индукцию некроза.
44. Фармацевтическая композиция, содержащая соединение по любому из пп.1-4, 9 или 14, или его фармацевтически приемлемый стереоизомер, соль или гидролизируемый in vivo сложный эфир, вместе с фармацевтически приемлемым носителем или эксципиентом.
45. Фармацевтическая композиция по п.44, где композиция подходит для топического введения.
46. Фармацевтическая композиция, содержащая соединение по любому из пп.1-4, 9 или 14, или его фармацевтически приемлемый стереоизомер, соль или гидролизируемый in vivo сложный эфир, в комбинации с одним или более других терапевтически активных средств.
RU2013133874/04A 2010-12-22 2011-12-22 Ингенол-3-ацилаты iii и ингенол-3-карбаматы RU2572549C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201061426378P 2010-12-22 2010-12-22
US61/426,378 2010-12-22
US201161448350P 2011-03-02 2011-03-02
US61/448,350 2011-03-02
US201161534055P 2011-09-13 2011-09-13
US61/534,055 2011-09-13
PCT/DK2011/000154 WO2012083953A1 (en) 2010-12-22 2011-12-22 Ingenol-3-acylates iii and ingenol-3-carbamates

Publications (2)

Publication Number Publication Date
RU2013133874A true RU2013133874A (ru) 2015-01-27
RU2572549C2 RU2572549C2 (ru) 2016-01-20

Family

ID=45491187

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013133874/04A RU2572549C2 (ru) 2010-12-22 2011-12-22 Ингенол-3-ацилаты iii и ингенол-3-карбаматы

Country Status (19)

Country Link
US (3) US9102687B2 (ru)
EP (1) EP2655323B1 (ru)
JP (2) JP5845283B2 (ru)
KR (1) KR20140010372A (ru)
CN (2) CN104529827B (ru)
AU (2) AU2011348637B2 (ru)
BR (1) BR112013015855A2 (ru)
CA (1) CA2822310A1 (ru)
ES (1) ES2659739T3 (ru)
HK (2) HK1191319A1 (ru)
IL (2) IL226904A (ru)
MX (1) MX339823B (ru)
MY (1) MY160501A (ru)
NZ (2) NZ710133A (ru)
RU (1) RU2572549C2 (ru)
SG (2) SG191196A1 (ru)
TW (2) TWI591047B (ru)
WO (1) WO2012083953A1 (ru)
ZA (1) ZA201304281B (ru)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP3822273B1 (en) 2012-06-13 2024-04-10 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
US9422309B2 (en) * 2012-06-26 2016-08-23 Leo Laboratories Limited 3-O-heteroaryl-ingenol
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
BR102012028120B8 (pt) * 2012-11-01 2022-08-02 Amazonia Fitomedicamentos Ltda Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI649318B (zh) 2013-04-19 2019-02-01 英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
CN104781229B (zh) * 2013-09-26 2017-03-01 三井化学株式会社 1,4－双(异氰酸甲酯基)环己烷、多异氰酸酯组合物、聚氨酯树脂、成型品、眼镜材料、眼镜框以及镜片
WO2015059574A1 (en) * 2013-10-25 2015-04-30 Leo Laboratories Limited A method for topically treating actinic keratosis on the trunk (except chest) or extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate)
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016083564A1 (en) * 2014-11-28 2016-06-02 Leo Laboratories Limited A method for topically treating actinic keratosis on the trunk (except chest) and extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate)
US20170258756A1 (en) * 2014-11-28 2017-09-14 Leo Laboratories Limited A Method for Topically Treating Actinic Keratosis on the Scalp with Ingenol 3-(3,5-diethylisoxazole-4-carboxylate)
EP3223812A1 (en) * 2014-11-28 2017-10-04 Leo Laboratories Limited A method for topically treating actinic keratosis on the full face or 250 cm2 on the chest with ingenol 3-(3,5-diethylisoxazole-4-carboxylate)
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016173651A1 (en) * 2015-04-29 2016-11-03 Leo Laboratories Limited Formulations comprising ingenol 3-(3,5-diethylisoxazole-4-carboxylate)
WO2016191837A1 (pt) * 2015-06-03 2016-12-08 Amazônia Fitomedicamentos Ltda. Método de preparação de ingenol-3-hexanoato, método de preparação de 3-etinil-3-hidroxi-4.7.7-trimetilbiciclo[4.1.0]heptano-2-carbaldeído e método de preparação do composto 2,2-dimetil-4-etinil-5-trifenilfosforanilideno-1,3-dioxano
WO2016191835A1 (pt) * 2015-06-03 2016-12-08 Amazônia Fitomedicamentos Ltda. Método de preparação de ingenol-5,20-acetonida, método de preparação de 3-etinil-3-hidroxi-4.7.7-trimetilbiciclo[4.1.0] heptano-2-carbaldeído, método de preparação do composto 2,2-dimetil-4-etinil-5 -trifenilfosforanilideno-1,3-dioxano e composto intermediário
WO2016191836A1 (pt) * 2015-06-03 2016-12-08 Amazônia Fitomedicamentos Ltda. Método de preparação de ingenol-3-dodecanoato, método de preparação de 3-etinil-3-hidroxi-4.7.7-trimetilbiciclo[4.1.0]heptano-2-carbaldeído e método de preparação de 2,2-dimetil-4-etinil-5-trifenilfosforanilideno-1,3-dioxano
WO2017089301A1 (en) * 2015-11-27 2017-06-01 Leo Laboratories Limited 3-triazolo-3-deoxy-ingenols
WO2017089300A1 (en) * 2015-11-27 2017-06-01 Leo Laboratories Limited 3-alkylamido-3-deoxy-ingenols
WO2017108927A1 (en) * 2015-12-22 2017-06-29 Leo Laboratories Limited Process for preparation of ingenol 3-(3.5-diethylisoxazole-4-carboxylate)
US10583140B2 (en) 2016-01-27 2020-03-10 Glaxosmithkline Intellectual Property Development Limited Ingenol analogs, pharmaceutical compositions and methods of use thereof
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN106619600B (zh) * 2016-03-28 2019-10-18 中国科学院遗传与发育生物学研究所 巨大戟醇及其衍生物在增强溶酶体生成中的应用
CN106083771A (zh) * 2016-06-13 2016-11-09 崔坤峰 卡比多巴的药物组合物及其治疗肝癌的医药用途
WO2018046337A1 (en) 2016-09-06 2018-03-15 Indena S.P.A. Solid forms of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) and method for preparing the same
US11370743B2 (en) 2017-05-12 2022-06-28 The Board Of Trustees Of The Leland Stanford Junior University Prodrug derivatives of protein kinase C modulators
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
AU2019262195A1 (en) 2018-05-04 2020-12-24 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
MX2022004513A (es) 2019-10-14 2022-07-19 Incyte Corp Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr).
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN112125918B (zh) * 2020-07-16 2021-10-01 中国科学院南海海洋研究所 芳香聚酮类化合物Talaromyoxaones A和B及其制备方法和应用
CN113150162A (zh) * 2021-03-11 2021-07-23 广东康辉集团有限公司 一种氨基甲酸酯类农药的抗体的制备方法和应用
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN114349707B (zh) * 2022-01-20 2024-01-09 中国医学科学院医药生物技术研究所 一种n-取代脲类化合物及其制备方法和应用
DE102022131737A1 (de) 2022-11-30 2024-06-06 Technische Universität München, Körperschaft des öffentlichen Rechts Pyrrol-Verbindung und Verfahren zur Herstellung einer Pyrrol-Verbindung

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955501A (en) 1986-06-11 1999-09-21 Procyon Pharmaceuticals, Inc. Protein kinase C modulators O
IL82811A0 (en) 1986-06-11 1987-12-20 Alder Res Center Corp Anti-inflammatory compositions containing methanol derivatives and novel compounds contained therein
US5145842A (en) * 1986-06-11 1992-09-08 Alder Research Center Limited Partnership Protein kinase c. modulators. d.
US5891870A (en) 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Protein kinase C modulators Q
US5891906A (en) 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Polyacetate-derived phorboids having anti-inflammatory and other uses
ATE185133T1 (de) * 1990-07-30 1999-10-15 Procyon Pharm Inc Proteinkinase-c-modulatoren mit entzündungshemmender und antiviraler aktivität
JPH07165600A (ja) * 1993-10-18 1995-06-27 Souyaku Gijutsu Kenkyusho:Kk 抗ウイルス剤
JPH08245505A (ja) * 1994-09-09 1996-09-24 Tosoh Corp ジテルペン誘導体、その製造法及びそれを有効成分として含有する抗腫瘍剤
JPH08245379A (ja) * 1995-01-12 1996-09-24 Soyaku Gijutsu Kenkyusho:Kk 抗ウイルス剤
JPH08268961A (ja) * 1996-02-28 1996-10-15 Procyon Pharmaceut Inc 抗炎症組成物
AUPO864097A0 (en) 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
AUPQ801700A0 (en) * 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
EP1628673B1 (en) * 2004-01-01 2007-03-07 Panacea Biotec Limited Pharmaceutical compositions comprising an extract of euphorbia prostrata
WO2006116897A1 (fr) * 2005-04-30 2006-11-09 Nihon University Diterpenes provenant de euphorbia kansui et leur utilisation
US8022103B2 (en) * 2005-07-13 2011-09-20 Salvia Sciences, Inc. Ester prodrugs of prostratin and related phorbol compounds
US20090215884A1 (en) * 2005-11-25 2009-08-27 Peplin Research Pty Ltd. Method for wound healing
GB0525680D0 (en) 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
AU2006201661A1 (en) * 2006-04-20 2007-11-08 Peplin Research Pty Ltd A method of diagnosis and treatment
CA2541903A1 (en) * 2006-04-20 2007-10-20 Peplin Research Pty. Ltd. A method of diagnosis and treatment
WO2008131491A1 (en) 2007-04-30 2008-11-06 Peplin Research Pty Ltd Treatment of virally induced lesions
CA2685516A1 (en) 2007-05-11 2008-11-20 Sonneborn Inc. Petrolatums having silicone-like properties
AU2010200429A1 (en) * 2009-02-05 2010-08-19 Ecobiotics Ltd Method of reducing or preventing blowfly strike

Also Published As

Publication number Publication date
AU2015210441B2 (en) 2016-10-06
NZ612446A (en) 2015-09-25
CN104529827B (zh) 2016-08-24
JP2014512331A (ja) 2014-05-22
AU2011348637B2 (en) 2015-08-20
ZA201304281B (en) 2014-08-27
CN103402977B (zh) 2016-01-20
BR112013015855A2 (pt) 2018-06-05
TWI548616B (zh) 2016-09-11
WO2012083953A1 (en) 2012-06-28
MY160501A (en) 2017-03-15
IL226904A (en) 2015-05-31
JP5845283B2 (ja) 2016-01-20
EP2655323A1 (en) 2013-10-30
RU2572549C2 (ru) 2016-01-20
US20140303150A1 (en) 2014-10-09
SG191196A1 (en) 2013-07-31
SG10201510566UA (en) 2016-01-28
CN104529827A (zh) 2015-04-22
US20150291551A1 (en) 2015-10-15
AU2011348637A1 (en) 2013-05-02
HK1191319A1 (zh) 2014-07-25
JP6111308B2 (ja) 2017-04-05
TWI591047B (zh) 2017-07-11
CA2822310A1 (en) 2012-06-28
US9102687B2 (en) 2015-08-11
US20170217910A1 (en) 2017-08-03
MX2013006995A (es) 2013-10-03
NZ710133A (en) 2016-08-26
KR20140010372A (ko) 2014-01-24
TW201623223A (zh) 2016-07-01
CN103402977A (zh) 2013-11-20
US9708286B2 (en) 2017-07-18
HK1206004A1 (en) 2015-12-31
EP2655323B1 (en) 2017-12-20
ES2659739T3 (es) 2018-03-19
AU2015210441A1 (en) 2015-09-03
IL238396A0 (en) 2015-06-30
MX339823B (es) 2016-06-13
JP2016029081A (ja) 2016-03-03
TW201249787A (en) 2012-12-16

Similar Documents

Publication Publication Date Title
RU2013133874A (ru) Ингенол-3-ацилаты iii и ингенол-3-карбаматы
JP2014512331A5 (ru)
DK1700856T3 (en) thiazole
RU2012126083A (ru) Производные аминооксазина
CA2553423A1 (en) Heterocyclic compounds for use in the treatment of cancer and the inhibition of angiogenesis
TW200400958A (en) Nitrogenous heterocyclic compound and pharmaceuticals thereof
CA2450400A1 (en) Medicinal compositions
JP6251275B2 (ja) ナトリウムチャンネル阻害剤、その製造方法およびその用途
RU2010106854A (ru) Производные 2-аза-бицикло[3.3.0]октана
JP2007519753A5 (ru)
JP2006502112A5 (ru)
WO2013009810A1 (en) Methods of treatment
EP2688872A1 (en) Amidopyrazole inhibitors of interleukin receptor-associated kinases
RU2016102137A (ru) Первичные карбоксамиды в качестве ингибиторов bik
AU2012288900B2 (en) Selective protein kinase inhibitors
AR038420A1 (es) Compuesto de amida, procedimiento para la preparacion del mismo, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende
BR112015020302B1 (pt) Derivado de pirazol, composição farmacêutica e composto intermediário
WO2013009830A1 (en) Methods of treatment
RU2004119438A (ru) Производные бензотиазола
JP2016512511A5 (ru)
CN106029656B (zh) 羟吲哚衍生物、其制备及其在治疗ampk相关疾病中的治疗用途
RU2011129786A (ru) Триазолопиридины в качестве ингибиторов фосфодиэстеразы для лечения кожных заболеваний
RU2013105450A (ru) Новые производные гомопиперзина в качестве ингибиторов протеинтирозинкиназ и их фармацевтическое применение
US7105538B2 (en) 2-pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants
BR112020022088A2 (pt) moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20181223